(Editor’s note: This just-published German study should offer reassurance to patients with Grade Group (Gleason 2) and above who have received a negative biopsy.
The incidence and mortality figures for both are about the same.
BTW, prostate cancer has surpassed breast cancer in UK and Australia/New Zealand. It may be coming here.
I have been an advisor on a study of trying to persuade women with the lowest grade breast cancer-Ductal carcinomain situ to go on surveillance.
DCISrefers to a non-invasive form of breast cancer where abnormal cells develop within the milk ducts of the breast, but have not spread to surrounding tissue. Sound familiar?
I was invited to help because we have been far more successful in persuading men to go on surveillance.
It's a rare situation. Men usually aren't all that interested in health.
But maybe in the face of potential incontinence and, worse, impotence, from aggressive treatment, guys get interested in being proactive.
Also, women and men have different attitudes about whether to be called survivors. Women with high- or low-grade breast cancer prefer to be called "survivors." Men, even with high-risk disease, don't like the "survivor" moniker. This per an Aussie study.
I had an epiphany when I saw this. First let me say that the similarities between the male prostate and the female breast are undeniable. The prostate is basically a little milk gland. PCa is tied to the BRCa gene, as is breast cancer. Women only get a biopsy when something is detected via palpation, the female DRE, or by imaging. At that point the biopsy is completely targeted. Men need the same 'arrangement'.
re: Antonio Westphalen, MD, University of Washington, The Radiology Report, review of the GOTEBORG-2 TRIAL, found 10.8.24, in, The Active Surveillor, "Prebiopsy MRIs Get Strong Support in New Scandinavian Study"
Your response should elicit clamor from activists worldwide to get a word in, edgewise; instead, silence! The Study received universal praise even given limitations highlighted by Westphalen: 1. Single Center; 2. Follow-up 3.9 years; 3. Homogenous population-white. If you haven't, read Howard's response, "Prostate Cancer Screenings Are A Lot of Mess-Time For A Major Reform"? Then, even if in the past you've shown no propensity, comment. His argument IS the problem; clearly each of us has a stake in resolution!
Good points, Harley,
The incidence and mortality figures for both are about the same.
BTW, prostate cancer has surpassed breast cancer in UK and Australia/New Zealand. It may be coming here.
I have been an advisor on a study of trying to persuade women with the lowest grade breast cancer-Ductal carcinomain situ to go on surveillance.
DCISrefers to a non-invasive form of breast cancer where abnormal cells develop within the milk ducts of the breast, but have not spread to surrounding tissue. Sound familiar?
I was invited to help because we have been far more successful in persuading men to go on surveillance.
It's a rare situation. Men usually aren't all that interested in health.
But maybe in the face of potential incontinence and, worse, impotence, from aggressive treatment, guys get interested in being proactive.
Check out this article and linked essay on breast and prostate cancer: https://howardwolinsky.substack.com/p/this-just-in-researchers-in-prostate?utm_source=publication-search
Also, women and men have different attitudes about whether to be called survivors. Women with high- or low-grade breast cancer prefer to be called "survivors." Men, even with high-risk disease, don't like the "survivor" moniker. This per an Aussie study.
I had an epiphany when I saw this. First let me say that the similarities between the male prostate and the female breast are undeniable. The prostate is basically a little milk gland. PCa is tied to the BRCa gene, as is breast cancer. Women only get a biopsy when something is detected via palpation, the female DRE, or by imaging. At that point the biopsy is completely targeted. Men need the same 'arrangement'.
I think if I was starting today Likely would never have been diagnosed. z
re: Antonio Westphalen, MD, University of Washington, The Radiology Report, review of the GOTEBORG-2 TRIAL, found 10.8.24, in, The Active Surveillor, "Prebiopsy MRIs Get Strong Support in New Scandinavian Study"
Your response should elicit clamor from activists worldwide to get a word in, edgewise; instead, silence! The Study received universal praise even given limitations highlighted by Westphalen: 1. Single Center; 2. Follow-up 3.9 years; 3. Homogenous population-white. If you haven't, read Howard's response, "Prostate Cancer Screenings Are A Lot of Mess-Time For A Major Reform"? Then, even if in the past you've shown no propensity, comment. His argument IS the problem; clearly each of us has a stake in resolution!